Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.

BMC Pulm Med · 2021 · PMC8325860 · PMID 34332555

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

On-treatment COPD-related exacerbations KM rates for TTF on-treatment overall, moderate, and severe COPD-related exacerbation at 12 months post-index were similar between matched cohorts; differences did not reach statistical significance (HR [95% CI]; overall: 0.93 [0.82, 1.05], moderate: 0.92 [0.80, 1.06], and severe: 1.07 [0.86, 1.33]; Additional file 1 : Fig. 1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.